GlassScriptPhysician profile
Vikash Chiraag Modi
NPI 1780905018
$7,649.30
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $573 · 2021: $1,124 · 2022: $1,994 · 2023: $2,633 · 2024: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,210.49 | 2021-2024 | |
| Novo Nordisk INC | $901.95 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Gilead Sciences, INC. | $674.58 | 2019-2024 | |
| Pfizer INC. | $454.58 | 2019-2024 | |
| Lilly USA, LLC | $412.72 | 2020-2024 | Mounjaro, Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $377.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $315.17 | 2020-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $295.88 | 2020-2021 | |
| Horizon Therapeutics Plc | $237.85 | 2019-2023 | Tepezza, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.36 | 2021-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $219.87 | 2022 | |
| Glaxosmithkline, LLC. | $184.15 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.43 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $141.53 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $134.29 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $123.65 | 2021-2023 | Rexulti |
| Akcea Therapeutics, INC. | $121.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $105.98 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $105.37 | 2021-2023 | Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $100.18 | 2022-2023 | Quviviq |
| Amgen INC. | $90.87 | 2019-2023 | Repatha, Otezla |
| Dynavax Technologies Corporation | $85.13 | 2019-2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $84.39 | 2019-2024 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Allergan, INC. | $81.82 | 2019-2020 | |
| Dexcom, INC. | $73.40 | 2022-2023 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $69.88 | 2023-2024 | Xelstrym |
| Viiv Healthcare Company | $68.10 | 2022-2023 | Apretude |
| Tris Pharma INC | $66.44 | 2023-2024 | Dyanavel Xr |
| Astellas Pharma US INC | $62.90 | 2022-2024 | Veozah, Myrbetriq |
| Impel Pharmaceuticals INC. | $51.10 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $44.44 | 2023 | Lyvispah |
| Shire North American Group INC | $38.06 | 2019 | |
| Upsher-Smith Laboratories LLC | $35.05 | 2021-2022 | |
| Sanofi Pasteur INC. | $30.97 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $27.61 | 2023-2024 | Contrave |
| Neos Therapeutics, LP | $27.28 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $24.44 | 2023 | Spravato |
| Amarin Pharma, INC. | $23.61 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.57 | 2024 | |
| Genentech USA, INC. | $17.55 | 2020 | |
| Lantheus Medical Imaging, INC. | $16.45 | 2022 | |
| Medtronic, INC. | $15.97 | 2023 | Venaseal |
| Phadia US INC. | $15.79 | 2023 | Immunocap |
| Dermira, INC. | $15.33 | 2020 | |
| Daiichi Sankyo INC. | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikash Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.